This Medical Stock Soared Over 80% In Pre-Market After Advancing Gene Therapy Program For ALS, Alzheimer's And Parkinson's Diseases
This Medical Stock Soared Over 80% In Pre-Market After Advancing Gene Therapy Program For ALS, Alzheimer's And Parkinson's Diseases
In Tuesday's pre-market trading, ANEW Medical, Inc. (NASDAQ:WENA) saw its shares surge nearly 80% following an announcement about the advancement of its patented Klotho gene therapy program for neurodegenerative disorders.
在週二的美股盤前交易中，ANEW Medical，Inc.（納斯達克：WENA）的股價因其針對神經退行性疾病的專利Klotho基因治療計劃前景的公告而大漲近80％。
What Happened: ANEW, a biopharmaceutical company that specializes in developing innovative therapies for neurological and age-related disorders, was trading at $2.460 at the time of writing, up from Monday's close at $1.450, according to Benzinga Pro data.
發生了什麼：ANEW是一家專門從事神經和老年性疾病創新療法開發的生物製藥公司，根據Benzinga Pro的數據，在撰寫本文時，該公司的股票價格爲2.460美元，與週一的收盤價1.450美元相比有所上漲。
ANEW's preliminary data indicates that maintaining high Klotho levels in the body could result in longer, healthier lives. Conversely, individuals with lower Klotho levels are more susceptible to neurodegenerative disorders such as ALS, Alzheimer's, and Parkinson's Disease. ANEW also intends to explore other age-related disorders associated with reduced Klotho levels.
ANEW的初步數據表明，保持身體中高Klotho水平可能會導致更長壽的健康生活。相反，Klotho水平較低的個體更容易患上肌萎縮側索硬化症（ALS）、阿爾茨海默病和帕金森病等神經退行性疾病。ANEW還打算探索與降低Klotho水平相關的其他老年性疾病。
ANEW's development plans encompass FDA Clinical Trials, Klotho Diagnostics, and Age-Related Disorders. Dr. Shalom Hirshman, M.D., Chief Medical Advisor and Board member, expressed that ANEW is well-positioned to significantly impact the treatment of ALS, Alzheimer's, and other neurodegenerative disorders.
ANEW的開發計劃包括FDA臨床試驗、Klotho診斷和老年性疾病。首席醫學顧問和董事會成員Dr. Shalom Hirshman認爲，ANEW有望在顯著影響ALS、阿爾茨海默病和其他神經退行性疾病的治療方面具有良好的地位。
Why It Matters: ANEW's advancements come amid a broader industry focus on neurodegenerative disorders. A recent study highlighted the complexities of Alzheimer's disease.
爲什麼重要：ANEW的進展是在整個醫療行業關注神經退行性疾病的背景下出現的。最近的一項研究強調了阿爾茨海默病的複雜性。
In June, Eli Lilly received FDA approval for its Alzheimer's therapy, Kisunla. Furthermore, they expanded their neuro pipeline with the addition of a preclinical ALS, dementia prospect. Even tech companies like Synchron Inc., backed by Jeff Bezos and Bill Gates, are entering the fray with plans to treat Parkinson's and epilepsy.
今年6月，Eli Lilly收到了針對阿爾茨海默病的Kisunla療法的FDA批准。此外，他們還通過加入一個臨床前ALS、癡呆前途的其它神經產品，擴大了他們的神經治療項目。甚至像由Jeff Bezos和Bill Gates支持的Synchron公司這樣的科技公司也計劃治療帕金森病和癲癇。
- Why Is HilleVax Stock Trading Lower On Monday?
- 爲什麼HilleVax股票週一交易下跌？
Photo: Courtesy of Marcin Janiec via Shutterstock
照片：由Shutterstock的Marcin Janiec免費提供
This story was generated using Benzinga Neuro and edited by Pooja Rajkumari
本報道使用Benzinga Neuro生成，並由Pooja Rajkumari編輯